-
Mashup Score: 2Patient-Derived Organoid-Based Prediction of Concurrent Chemoradiotherapy Response in Oesophageal Cancer - European Medical Journal - 2 year(s) ago
Oesophageal carcinoma is the eighth most common malignancy worldwide and the seventh most common cause of death in men…
Source: European Medical JournalCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0
Sugemalimab after definitive concurrent or sequential chemoradiotherapy could be an effective consolidation therapy for patients with stage III NSCLC whose disease has not progressed after sequential or concurrent chemoradiotherapy. Longer follow-up is needed to confirm this conclusion.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the February issue: interim results of GEMSTONE-301 – #Sugemalimab versus placebo after concurrent or sequential #chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell https://t.co/QWqVcr6TLn #lungcancer #NSCLC https://t.co/9UhGGCV1MT
-
-
Mashup Score: 10
RAPIDS was able to predict pathological complete response to neoadjuvant chemoradiotherapy based on pretreatment radiopathomics images with high accuracy and robustness and could therefore provide a novel tool to assist in individualised management of locally advanced rectal cancer.
Source: The Lancet Digital HealthCategories: Future of Medicine, Latest HeadlinesTweet-
New Research: 'Development and validation of a #radiopathomics model to predict pathological complete response to neoadjuvant #chemoradiotherapy in locally advanced rectal #cancer: a multicentre observational study'. @umichmedicine @MDAndersonNews https://t.co/yUmbiIe5ip https://t.co/WG6HMzmwc5
-
-
Mashup Score: 0
Sugemalimab after definitive concurrent or sequential chemoradiotherapy could be an effective consolidation therapy for patients with stage III NSCLC whose disease has not progressed after sequential or concurrent chemoradiotherapy. Longer follow-up is needed to confirm this conclusion.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Online first: interim results of GEMSTONE-301 – #Sugemalimab versus placebo after concurrent or sequential #chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell #lungcancer #NSCLC https://t.co/QWqVcqPiTP
-
-
Mashup Score: 1Risk factors for pulmonary complications after neoadjuvant chemoradiotherapy followed by surgery for non-small cell lung cancer - PubMed - 2 year(s) ago
The nomogram constructed with factors identified in multivariable analysis could serve as a reliable tool for evaluating the risk of PPCs in the patients who underwent neoadjuvant CRTx for NSCLC.
Source: PubMedCategories: Latest Headlines, PulmonologyTweet-
Risk factors for #pulmonary #complications after #neoadjuvant #chemoradiotherapy followed by #surgery for #non- #small #cell #lung #cancer #LungCancer #NSCLC https://t.co/HGdORf8VQc https://t.co/63zE2Fnx3R
-
-
Mashup Score: 4thoracic-radiotherapy - 3 year(s) ago
Dosing of Thoracic Radiotherapy in Limited Stage Small Cell Lung CancerBy Sarah LaCorteAlthough small cell lung cancer (SCLC) constitutes 13 percent of all lung cancer diagnoses, there has been little progress in the treatment of SCLC in the past 2 decades. Currently, the majority of patients with limited stage SCLC (LSCLC) are treated with a high dose once-daily…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A Phase III trial analyzed if administering high-dose TRT would improve overall survival, compared with standard 45 Gy standard twice-daily TRT, in #LSCLC patients treated with #chemoradiotherapy: https://t.co/zdPlzHPTsA #NSCLC #LungCancer #OncNews #MedicalNews #ASCORewind https://t.co/lhf9qEE9TV
-
-
Mashup Score: 6
Japanese researchers identified chromosome aberrations as a new biomarker in predicting an esophageal cancer patient’s risk of experiencing severe chemoradiotherapy side effects.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
#Chromosomeaberrations may predict risk of severe #chemoradiotherapy side effects @Hiroshima_Univ https://t.co/Oz4xWCPk4i
-
-
Mashup Score: 0Patient-Derived Organoid-Based Prediction of Concurrent Chemoradiotherapy Response in Oesophageal Cancer - European Medical Journal - 3 year(s) ago
Oesophageal carcinoma is the eighth most common malignancy worldwide and the seventh most common cause of death in men…
Source: European Medical JournalCategories: Gastroenterology, Latest HeadlinesTweet-
The aim of this study was to evaluate the predictive power of CCRT response using a primary three-dimensional cell (organoid) culture in oesophageal cancer. Read it here: https://t.co/xmLHc0YpYV #oesophagealcancer #gastroenterology #chemoradiotherapy
-
-
Mashup Score: 0
Background Endoscopic resection (ER) has been widely implemented for cT1N0 esophageal squamous cell carcinoma (ESCC). Additional therapy, including esophagectomy and chemoradiotherapy (CRT), is sometimes required after noncurative ER. Methods We retrospectively reviewed 108 patients who received any additional treatment following noncurative ER (positive vertical margins, lymphovascular invasion,…
Source: Annals of Surgical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Additional Treatment Following Noncurative #EndoscopicResection for #EsophagealSquamousCellCarcinoma : A Comparison of Outcomes between #Esophagectomy and #Chemoradiotherapy . https://t.co/AfResCza3h #VisualAbstract @McMastersKelly https://t.co/dhM577Uvzk
-
-
Mashup Score: 4
Intensification of chemotherapy using FOLFIRINOX before preoperative chemoradiotherapy significantly improved outcomes compared with preoperative chemoradiotherapy in patients with cT3 or cT4 M0 rectal cancer. The significantly improved disease-free survival in the neoadjuvant chemotherapy group and the decreased neurotoxicity indicates that the perioperative approach is more efficient and better…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in our May issue: : UNICANCER-PRODIGE 23 phase 2 trial: #Neoadjuvant #chemotherapy with FOLFIRINOX and #preoperative #chemoradiotherapy for patients with locally advanced #rectalcancer #crcsm https://t.co/cRqMv48yQo
-
Patient-Derived Organoid-Based Prediction Of Concurrent #Chemoradiotherapy Response In #Oesophageal #Cancer https://t.co/Ljat12YX5A https://t.co/6dbHNtrehX